Karyopharm Therapeutics I...

NASDAQ: KPTI · Real-Time Price · USD
5.96
1.31 (28.17%)
At close: Aug 15, 2025, 3:59 PM
5.70
-4.36%
After-hours: Aug 15, 2025, 06:25 PM EDT

Karyopharm Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
145.24M 146.03M 157.07M 209.82M
Cost of Revenue
6.01M 4.94M 5.21M 3.4M
Gross Profit
139.23M 141.09M 151.86M 206.42M
Operating Income
-119.44M -129.54M -142.2M -98.27M
Interest Income
7.4M 10.94M 2.36M 582K
Pretax Income
-76.36M -142.78M -164.92M -123.82M
Net Income
-76.42M -143.1M -165.29M -124.09M
Selling & General & Admin
115.44M 131.88M 145.4M 143.85M
Research & Development
143.23M 138.75M 148.66M 160.84M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
258.67M 270.63M 294.06M 304.69M
Interest Expense
37.42M 23.82M 25M 26.05M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
264.68M 275.57M 299.28M 308.09M
Income Tax Expense
57K 323K 369K 268K
Shares Outstanding (Basic)
8.12M 7.61M 5.46M 5.01M
Shares Outstanding (Diluted)
8.12M 7.61M 5.46M 5.01M
EPS (Basic)
-9.41 -18.79 -30.28 -24.75
EPS (Diluted)
-9.41 -18.79 -30.28 -24.75
EBITDA
-38.6M -118.42M -139.31M -96.98M
EBIT
-38.94M -118.95M -139.93M -97.77M
Depreciation & Amortization
340K 530K 621K 789K